13F filer · CIK 1579853
SENZAR ASSET MANAGEMENT, LLC
New York, NY · filing since Q4 2013 · last filing Oct 31, 2018
Reported value
$406.2M
+$11.5M vs prior
Positions
23
New / sold out
7 / 12
Added / reduced
8 / 8
Turnover
45.9%
buys $189.7M · sells $183.8M
Top-10 weight
76.7%
Biggest buys vs Q1 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | NEUROCRINE BIOSCIENCES INC | +749,200 | – | +$34.5M |
| New | LLYLILLY ELI & CO | +415,200 | – | +$34.2M |
| Added | MYLAN N V | +690,400 | +318.6% | +$26.8M |
| New | AERIE PHARMACEUTICALS INC | +391,400 | – | +$20.6M |
| New | CVSCVS HEALTH CORP | +226,600 | – | +$18.2M |
| New | DAVITA INC | +258,800 | – | +$16.8M |
| Added | HALOZYME THERAPEUTICS INC | +597,400 | +17.1% | +$7.7M |
| Added | EXPRESS SCRIPTS HLDG CO | +118,000 | +22.5% | +$7.5M |
| New | ACHILLION PHARMACEUTICALS IN | +1,082,100 | – | +$5.0M |
| Added | ALDER BIOPHARMACEUTICALS INC | +342,700 | +159.3% | +$3.9M |
5 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2017
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SANOFI | -1,538,908 | -100.0% | $-69.6M |
| Sold out | BIOVERATIV INC | -343,800 | -100.0% | $-18.7M |
| Sold out | MIMEDX GROUP INC | -1,692,850 | -100.0% | $-16.1M |
| Sold out | GLOBUS MED INC | -447,100 | -100.0% | $-13.2M |
| Sold out | MYRIAD GENETICS INC | -518,800 | -100.0% | $-10.0M |
| Sold out | SELECT MED HLDGS CORP | -662,200 | -100.0% | $-8.8M |
| Sold out | TENET HEALTHCARE CORP | -484,300 | -100.0% | $-8.6M |
| Sold out | ORTHOFIX INTL N V | -188,908 | -100.0% | $-7.2M |
| Sold out | DIPLOMAT PHARMACY INC | -445,200 | -100.0% | $-7.1M |
| Reduced | CORIUM INTL INC | -704,500 | -46.7% | $-5.3M |
10 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2017
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | HALOZYME THERAPEUTICS INCCOM | 4,087,264 | $52.4M | 12.90% |
| 2 | EXPRESS SCRIPTS HLDG COCOM | 641,301 | $40.9M | 10.08% |
| 3 | MYLAN N VSHS EURO | 907,100 | $35.2M | 8.67% |
| 4 | NEUROCRINE BIOSCIENCES INCCOM | 749,200 | $34.5M | 8.49% |
| 5 | LLYLILLY ELI & CO | 415,200 | $34.2M | 8.41% |
| 6 | ANTHEM INCCOM | 144,350 | $27.2M | 6.69% |
| 7 | GILEAD SCIENCES INCCOM | 373,800 | $26.5M | 6.51% |
| 8 | ABBOTT LABSCOM | 450,700 | $21.9M | 5.39% |
| 9 | AERIE PHARMACEUTICALS INCCOM | 391,400 | $20.6M | 5.06% |
| 10 | CVSCVS HEALTH CORP | 226,600 | $18.2M | 4.49% |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.